Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Husby, S, Favero, F, Nielsen, C, Sørensen, BS, Bæch, J, Grell, K, Hansen, JW, Rodriguez-Gonzalez, FG, Haastrup, EK, Fischer-Nielsen, A, Andersen, P, Arboe, B, Sækmose, SG, Hansen, PB, Christiansen, I, Clasen-Linde, E, Knudsen, LM, Ebbesen, LH, Segel, EK, Josefsson, P, Thorsgaard, M, El-Galaly, TC, Brown, P, Weischenfeldt, J, Larsen, TS & Grønbæk, K 2020, 'Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study', Leukemia, bind 34, nr. 12, s. 3256-3268. https://doi.org/10.1038/s41375-020-0795-z

APA

CBE

Husby S, Favero F, Nielsen C, Sørensen BS, Bæch J, Grell K, Hansen JW, Rodriguez-Gonzalez FG, Haastrup EK, Fischer-Nielsen A, Andersen P, Arboe B, Sækmose SG, Hansen PB, Christiansen I, Clasen-Linde E, Knudsen LM, Ebbesen LH, Segel EK, Josefsson P, Thorsgaard M, El-Galaly TC, Brown P, Weischenfeldt J, Larsen TS, Grønbæk K. 2020. Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study. Leukemia. 34(12):3256-3268. https://doi.org/10.1038/s41375-020-0795-z

MLA

Vancouver

Author

Husby, Simon ; Favero, Francesco ; Nielsen, Christian ; Sørensen, Betina S ; Bæch, John ; Grell, Kathrine ; Hansen, Jakob W ; Rodriguez-Gonzalez, Francisco G ; Haastrup, Eva K ; Fischer-Nielsen, Anne ; Andersen, Pernille ; Arboe, Bente ; Sækmose, Susanne G ; Hansen, Per B ; Christiansen, Ilse ; Clasen-Linde, Erik ; Knudsen, Lene Meldgaard ; Ebbesen, Lene H ; Segel, Erik K ; Josefsson, Pär ; Thorsgaard, Michael ; El-Galaly, Tarec C ; Brown, Peter ; Weischenfeldt, Joachim ; Larsen, Thomas S ; Grønbæk, Kirsten. / Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT : a national population-based cohort study. I: Leukemia. 2020 ; Bind 34, Nr. 12. s. 3256-3268.

Bibtex

@article{bb327abdd82046a595be8cd32f4ae636,
title = "Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study",
abstract = "Clonal hematopoiesis of indeterminate potential (CHIP) is suspected of being a risk factor for patients with cancer. This study aimed to assess the clinical consequences of CHIP in patients with lymphoma intended for high-dose chemotherapy and autologous stem-cell transplantation (ASCT) in a population-based setting. We identified 892 lymphoma patients who had undergone stem cell harvest at all transplant centers in Denmark. A total of 565 patients had an available harvest sample, which was analysed for CHIP by next-generation sequencing, and the median follow-up was 9.1 years. Of the patients who were intended for immediate ASCT, 25.5% (112/440) carried at least one CHIP mutation. In contrast to previous single-center studies CHIP was not associated with inferior overall survival (OS) in multivariate analyses. However, patients with mutations in genes of the DNA repair pathway (PPM1D, TP53, RAD21, BRCC3) had a significant inferior OS (HR after 1 year of follow-up 2.79, 95% confidence interval 1.71-4.56; p < 0.0001), which also was evident in multivariate analysis (p = 0.00067). These patients had also increased rates of therapy-related leukemia and admission to intensive care. Furthermore, in patients who did not undergo immediate ASCT, a significant inferior OS of individuals with DNA repair mutations was also identified (p = 0.003).",
author = "Simon Husby and Francesco Favero and Christian Nielsen and S{\o}rensen, {Betina S} and John B{\ae}ch and Kathrine Grell and Hansen, {Jakob W} and Rodriguez-Gonzalez, {Francisco G} and Haastrup, {Eva K} and Anne Fischer-Nielsen and Pernille Andersen and Bente Arboe and S{\ae}kmose, {Susanne G} and Hansen, {Per B} and Ilse Christiansen and Erik Clasen-Linde and Knudsen, {Lene Meldgaard} and Ebbesen, {Lene H} and Segel, {Erik K} and P{\"a}r Josefsson and Michael Thorsgaard and El-Galaly, {Tarec C} and Peter Brown and Joachim Weischenfeldt and Larsen, {Thomas S} and Kirsten Gr{\o}nb{\ae}k",
year = "2020",
month = dec,
doi = "10.1038/s41375-020-0795-z",
language = "English",
volume = "34",
pages = "3256--3268",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "12",

}

RIS

TY - JOUR

T1 - Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT

T2 - a national population-based cohort study

AU - Husby, Simon

AU - Favero, Francesco

AU - Nielsen, Christian

AU - Sørensen, Betina S

AU - Bæch, John

AU - Grell, Kathrine

AU - Hansen, Jakob W

AU - Rodriguez-Gonzalez, Francisco G

AU - Haastrup, Eva K

AU - Fischer-Nielsen, Anne

AU - Andersen, Pernille

AU - Arboe, Bente

AU - Sækmose, Susanne G

AU - Hansen, Per B

AU - Christiansen, Ilse

AU - Clasen-Linde, Erik

AU - Knudsen, Lene Meldgaard

AU - Ebbesen, Lene H

AU - Segel, Erik K

AU - Josefsson, Pär

AU - Thorsgaard, Michael

AU - El-Galaly, Tarec C

AU - Brown, Peter

AU - Weischenfeldt, Joachim

AU - Larsen, Thomas S

AU - Grønbæk, Kirsten

PY - 2020/12

Y1 - 2020/12

N2 - Clonal hematopoiesis of indeterminate potential (CHIP) is suspected of being a risk factor for patients with cancer. This study aimed to assess the clinical consequences of CHIP in patients with lymphoma intended for high-dose chemotherapy and autologous stem-cell transplantation (ASCT) in a population-based setting. We identified 892 lymphoma patients who had undergone stem cell harvest at all transplant centers in Denmark. A total of 565 patients had an available harvest sample, which was analysed for CHIP by next-generation sequencing, and the median follow-up was 9.1 years. Of the patients who were intended for immediate ASCT, 25.5% (112/440) carried at least one CHIP mutation. In contrast to previous single-center studies CHIP was not associated with inferior overall survival (OS) in multivariate analyses. However, patients with mutations in genes of the DNA repair pathway (PPM1D, TP53, RAD21, BRCC3) had a significant inferior OS (HR after 1 year of follow-up 2.79, 95% confidence interval 1.71-4.56; p < 0.0001), which also was evident in multivariate analysis (p = 0.00067). These patients had also increased rates of therapy-related leukemia and admission to intensive care. Furthermore, in patients who did not undergo immediate ASCT, a significant inferior OS of individuals with DNA repair mutations was also identified (p = 0.003).

AB - Clonal hematopoiesis of indeterminate potential (CHIP) is suspected of being a risk factor for patients with cancer. This study aimed to assess the clinical consequences of CHIP in patients with lymphoma intended for high-dose chemotherapy and autologous stem-cell transplantation (ASCT) in a population-based setting. We identified 892 lymphoma patients who had undergone stem cell harvest at all transplant centers in Denmark. A total of 565 patients had an available harvest sample, which was analysed for CHIP by next-generation sequencing, and the median follow-up was 9.1 years. Of the patients who were intended for immediate ASCT, 25.5% (112/440) carried at least one CHIP mutation. In contrast to previous single-center studies CHIP was not associated with inferior overall survival (OS) in multivariate analyses. However, patients with mutations in genes of the DNA repair pathway (PPM1D, TP53, RAD21, BRCC3) had a significant inferior OS (HR after 1 year of follow-up 2.79, 95% confidence interval 1.71-4.56; p < 0.0001), which also was evident in multivariate analysis (p = 0.00067). These patients had also increased rates of therapy-related leukemia and admission to intensive care. Furthermore, in patients who did not undergo immediate ASCT, a significant inferior OS of individuals with DNA repair mutations was also identified (p = 0.003).

U2 - 10.1038/s41375-020-0795-z

DO - 10.1038/s41375-020-0795-z

M3 - Journal article

C2 - 32203146

VL - 34

SP - 3256

EP - 3268

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 12

ER -

ID: 61628523